Treatment of oral mucosal manifestations of chronic graft-versus-host disease: dexamethasone vs. budesonide

Yehuda Zadik, Sharon Elad, Anat Shapira, Michael Y. Shapira*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations

Abstract

Introduction: The oral mucosa is commonly involved in chronic graft-versus-host disease (cGVHD). Oral mucosal cGVHD markedly affect individual’s daily function and wellbeing. In some cases, it might become a life threating complication. Areas covered: This article describes the rationale for treatment, method of topical application in the oral cavity, evidence supporting the topical administration of dexamethasone and budesonide for oral cGVHD, and their adverse effects. Expert opinion: Evidence supports the use of topical dexamethasone and budesonide for treatment of oral cGVHD. Topical corticosteroid choice for oral cGVHD, takes into consideration the potency, bioavailability, preferred concentration, and possible adverse effects. Budesonide’s pharmacological characteristics mark it as a preferable topical agent for oral cGVHD.

Original languageAmerican English
Pages (from-to)235-242
Number of pages8
JournalExpert Opinion on Pharmacotherapy
Volume18
Issue number3
DOIs
StatePublished - 11 Feb 2017

Bibliographical note

Publisher Copyright:
© 2017 Informa UK Limited, trading as Taylor & Francis Group.

Keywords

  • Budesonide
  • chronic graft-versus-host disease
  • dexamethasone
  • hematopoietic stem cell transplantation
  • mucosa
  • oral
  • oral medicine
  • pain

Fingerprint

Dive into the research topics of 'Treatment of oral mucosal manifestations of chronic graft-versus-host disease: dexamethasone vs. budesonide'. Together they form a unique fingerprint.

Cite this